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Under oxidative stress conditions, several constitutive cellular defense systems are activated, which involve both enzymatic systems
and molecules with antioxidant properties such as glutathione and vitamins. In addition, proteins containing reactive sulfhydryl
groups may eventually undergo reversible redox modiﬁcations whose products act as protective shields able to avoid further
permanent molecular oxidative damage either in stressful conditions or under pathological circumstances. After the recovery of
normal redox conditions, the reduced state of protein sulfhydryl groups is restored. In this context, carbonic anhydrases (CAs)
III and VII, which are human metalloenzymes catalyzing the reversible hydration of carbon dioxide to bicarbonate and proton,
have been identiﬁed to play an antioxidant role in cells where oxidative damage occurs. Both proteins are mainly localized in
tissues characterized by a high rate of oxygen consumption, and contain on their molecular surface two reactive cysteine
residues eventually undergoing S-glutathionylation. Here, we will provide an overview on the molecular and functional features
of these proteins highlighting their implications into molecular processes occurring during oxidative stress conditions.
1. Introduction
In physiological conditions, reactive oxygen species (ROS)
are generated intracellularly as a result of metabolism in per-
oxisomes, mitochondria, and by several cytosolic enzymes
[1]. However, their generation is also triggered by exogenous
sources, such as UV-light, chemotherapeutics, inﬂammatory
cytokines, and ionizing radiations [1, 2]. Normally, the levels
of ROS in cells are tightly regulated by sophisticated enzy-
matic and nonenzymatic antioxidant defense systems, such
as catalase, superoxide dismutase, glutathione peroxidase,
glutathione (GSH), and vitamins (vitamin A, C, and E). Gen-
erated ROS, within certain boundaries, are fundamental to
preserve cell homeostasis and serve as important regulatory
mechanisms for many cellular activities [1]. When ROS
levels are unbalanced, detrimental eﬀects on the physiologi-
cal functions of the cell may occur. This can eventually lead
to accelerated aging, age-related diseases, and, ultimately, to
cell death [1]. ROS, which include oxygen-centered radical
species, as hydroxyl radical (·OH), superoxide anion
(O2
·-), and peroxyl radical (R-O2
·); and nonradical com-
pounds, as hydrogen peroxide (H2O2), hypochlorous acid
(HOCl), and ozone (O3), are known to modify proteins,
nucleic acids, and lipids through a number of oxidative
pathways [3–6].
In proteins, oxidative posttranslational modiﬁcations can
either be permanent, as result of irreversible molecular oxida-
tive damage, or temporary, which prevent lasting oxidative
damage under stressful cellular conditions [7]. Cysteine is
the most susceptible residue toward oxidative modiﬁcations.
This is a nonabundant amino acid, being less than 3% com-
pared to the other residues of the mammalian proteome
[8]. It is nucleophilic, redox sensitive, and can undergo
reversible and irreversible modiﬁcations in response to an
altered localized redox environment [9]. Cysteine thiols have
a pKa value of about 8.5 [10]. For this reason, they are not
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reactive at physiological pH values. However, within the pro-
tein three-dimensional structure, cysteines can be aﬀected by
the presence of speciﬁc residues altering their reactivity. In
particular, the spatial proximity of acidic residues will raise
the pKa value of thiol group, leaving cysteine uncharged
and making it less prone to modiﬁcation [11]. On the con-
trary, an alkaline environment given by the vicinal presence
of basic residues can lower the corresponding pKa value,
facilitating thiol deprotonation [11]. Cys modiﬁcation is also
aﬀected by accessibility, since steric factors may prevent its
alteration, even if the pKa of the thiol residue is relatively
low [12]. For these reasons, oxidation of reactive cysteines
is a highly selective process [13–15].
The thiolate anion renders proteins susceptible targets for
a variety of oxidativemodiﬁcations, generating cysteine deriv-
atives containing intramolecular and intermolecular disulﬁde
linkages, adducted species bearing disulﬁde bonds with low-
molecular mass nonprotein thiols (mainly with GSH and to
a lesser extent with free cysteine, forming PS-SG and PS-SCys,
resp.) and sulfenic acid (P-SOH) (Figure 1). Sulfenic acid-
containing proteins can undergo glutathionylation or be fur-
ther oxidized leading to the irreversible formation of sulﬁnic
(P-SO2H) and/or sulfonic acid (P-SO3H) derivatives [9].
The latter oxidative modiﬁcations often can irreversibly alter
the structure and function of the involved protein. On the
contrary, protein S-glutathionylation is a reversible reaction
that can be eﬃciently reverted primarily by glutaredoxin
(GRx) [16] and also by thioredoxin (TRx) [17], sulﬁredoxin
[18], or spontaneously in the presence of a high ratio of
GSH/GSSG [19] (Figure 1). In oxidative stress conditions,
protein thiolate anion may also undergo S-nitrosylation with
reactive nitrosative species (RNS). Resulting protein S-
nitrosothiol has a relatively short half-life since it reacts with
physiological GSH forming the S-glutathionylated protein
[9, 20, 21] (Figure 1).
Reversible S-modiﬁcation can aﬀect protein structure
and function; thus, it has been reported as a molecular switch
able to reversibly activate or deactivate regulatory processes,
such as serving to transduce redox signals, control of gene
expression, cell proliferation, and apoptosis [15, 22]. Besides
its role in redox signal transduction, S-glutathionylation has
been suggested also to be a cellular mechanism by which cells
preserve enzyme functionality from further irreversible oxi-
dation [22, 23].
Among the diﬀerent antioxidant systems that cells have
developed, it has been reported that proteins containing reac-
tive cysteines could play a protective role against oxidative
insult occurring either in stressful conditions or under path-
ological circumstances. These proteins participate in the
cellular defense system by means of reversible thiol modiﬁca-
tion of their cysteine residues. In this view, we here report on
the antioxidant role of two human metalloenzymes, namely,
carbonic anhydrases (CAs) III and VII, whose function in
mediating the oxidative insult and aging has been recently
reported [24].
CAs are ubiquitous enzymes [25], encoded by seven
genetically distinct gene families: α-, β-, γ-, δ-, ζ-, η-, and
θ-CAs [25–30]. Human CAs (hCAs) belong to the α-class
with ﬁfteen isoforms being so far identiﬁed that diﬀer in
tissue distribution, catalytic activity, response to inhibitors,
and cellular localization. Indeed, ﬁve isoforms are cytosolic
(CAs I–III, VII, and XIII), four are membrane-associated
(CAs IV, IX, XII, and XIV), two are mitochondrial (CAs
VA and VB), and one is secreted in milk and saliva (CA
VI) [25, 31, 32]. CAs catalyze a simple physiological reaction,
the reversible hydration of carbon dioxide to bicarbonate and
proton, following a two-step mechanism [33, 34]. Several
studies reported that CAs are involved in a variety of physio-
logical processes, such as acid-base balance, respiration,
carbon dioxide and ion transport, bone resorption, and urea-
genesis. Consequently, abnormal levels or activities of these
enzymes have been often associated with diﬀerent human
pathological conditions [31, 35].
Among the cytosolic CA isoforms, CA III and CA VII are
enzymes having properties that deserve further attention
[24]. In particular, recent studies showed that these proteins
are mainly present in tissues characterized by a high oxygen
consumption rate, such as skeletal muscle, liver, and brain,
where they could participate in cell defense processes coun-
teracting oxidative damage [24, 36]. In this review, by exam-
ining CA III and CA VII functional and structural features,
we will provide insights into their newly proposed protective
role against oxidative stress.
1.1. Tissue Distribution, Catalytic Activity, and Molecular
Features of CA III and CA VII. The distribution pattern of
CA III has been investigated using diﬀerent techniques, such
asWestern blotting and immunohistochemistry experiments,
indicating that this isoform is highly expressed in liver and
skeletal muscle [37] and at lower levels in other tissues
[37–45]. CA VII was thought initially to have a more limited
tissue distribution, being detected only in some brain regions
including the cortex, hippocampus, and thalamus where it
plays a role as a molecular switch for GABAergic excitation
[46–48]. Subsequently, CA VII has been found also in other
human tissues such as colon, muscle, and liver [49], reveal-
ing a strong similarity with CA III.
CA III and CA VII present also high similarity in their
primary structures with 49% sequence identity (Figure 2).
Notably, they contain a higher number of cysteine residues
(5 and 4, resp.) with respect to other cytosolic CAs having
only a single cysteine (Figure 2) [24].
It has been reported that both enzymes have two highly
reactive cysteines on the protein surface, namely, Cys183
and Cys188 for CA III and Cys183 and Cys217 for CA VII
(numbering refers to hCA I isoform [50]). These cysteines
have been reported to be S-glutathionylated both in vitro
[51] and in vivo [52, 53], without aﬀecting enzyme catalytic
activity [51, 53]. Thus, the localization of CA III and CA
VII in organs and tissues characterized by a high propensity
for oxidative stress, combined with the presence of reactive
sulfhydryls in their primary structure, provided the ﬁrst evi-
dence that these enzymes may act as oxyradical scavengers
involved in cell protection from oxidative damage.
Despite the above-described similarities, CA III and CA
VII present a very diﬀerent catalytic eﬃciencies for hydration
of CO2, with CA VII being one of the most eﬃcient catalysts
among mammalian isoforms [51, 54] and CA III being the
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worst one (kcat/KM of 0.3× 106M−1 s−1 for CA III and of
7.2× 107M−1 s−1 for CA VII) [55].
Structural studies on hCA III [56] and on a mutated form
of hCA VII, named dmCA VII [54, 57], showed that both
enzymes adopt a three-dimensional arrangement similar to
that of other cytosolic CAs [50, 58]. Both proteins are mono-
meric, and their fold presents a central ten-stranded β-sheet
surrounded by additional β-strands and several α- and 310-
helices. Their active site is located in a large conical cavity,
containing the catalytic zinc ion at the base, which is coordi-
nated by three conserved histidine residues (His94, His96,
and His119). The X-ray structures of bovine and rat CA III
have also been solved [53, 59].
Remarkably, the structural analysis of rat CA III provided
very interesting data clarifying the molecular determinants
responsible for the above-mentioned high redox reactivity
of Cys183 and Cys188. Indeed, these two residues, which
are located on the molecular surface of the protein, were
SH
Nitrosative stress
Oxidative stress
S−
−H+
S-SG
S (NO) S-SG
S-OH
GSH
GRx (TRx)
S-SG
ROS
SO2− SO3
−
S-SCys
GSH
GSH
GRx (TRx)
CysH
+P
P
P
P
P
P
PP
P P
Figure 1: Schematic representation of protein oxidative modiﬁcations involving its reactive cysteine and nonprotein thiols with low
molecular weight mass.
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Figure 2: Sequence alignment of cytosolic hCAs. Reactive cysteines of CA III and VII are highlighted in green and reduced ones in yellow,
whereas CA VII cysteines involved in the formation of an intramolecular disulﬁde bond are in pink.
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found S-glutathionylated in the crystal structure [53]. Since
analysis of the binding sites gave no evidence for a speciﬁc rec-
ognition of GSH, it was suggested that S-glutathionylation
was due to the high reactivity of Cys183 and Cys188 and to
the great abundance of GSH in cell, which reaches in vivo
millimolar concentration [2, 23, 60]. The disulﬁde linkage
between the cysteine residue and the GSH molecule does
not alter the overall structure of the protein, nor the confor-
mation of residues located close to Cys183 and Cys188, in
agreement with the observation that S-glutathionylation does
not have eﬀect on the catalytic activity of the enzyme [53].
Moreover, the electron density maps of the two Cys-GSH
adducts indicated a conformational ﬂexibility of the glu-
tathionyl moieties, with the disulﬁde bridge involving
Cys183 adopting two diﬀerent orientations, and that involv-
ing Cys188 only one.
Among the two cysteines, Cys188 is located in an envi-
ronment characterized by a lower negative charge, thus
explaining its greater propensity to react [61]. On the con-
trary, Cys183 is located in a depression of the surface show-
ing a greater negative charge, making this residue less
reactive. Two positively charged residues surrounding
Cys188, namely, Lys213 and Arg189, were hypothesized to
act as main modulators of thiol reactivity, lowering its pKa
value. Interestingly, mutagenesis studies showed that only
Lys213 is responsible for the lowering of the pKa value of
Cys188, whereas Arg189 seems not to aﬀect it. In addition,
the acid residues Asp190 and Glu214 were also found to
interact with the thiol of Cys188, decreasing its reactivity
and partially counteracting the presence of the above-
mentioned basic residues (Figures 3(a) and 3(b)) [61]. The
crystallographic structure of S-glutathionylated CA III pro-
vided also information on the diﬀerent reactivity of adducted
protein thiols towards the process of deglutathionylation,
with the Cys188-glutathione adduct being more accessible
to nucleophilic attack compared to the corresponding
Cys183-adduct, due to its greater steric accessibility [53].
In the case of CA VII, Cys54 and Cys178 were proved to
be involved in an intramolecular disulﬁde bond, whereas the
two remaining cysteines, Cys183 and Cys217, are exposed on
the molecular surface [54, 57]. At present, no crystallo-
graphic information is available for S-glutathionylated
Cys183 and Cys217. Thus, starting from the crystallographic
structure of dmCA VII, we have built a model of hCA VII
and used it to investigate the chemical environment poten-
tially aﬀecting Cys183 and Cys217 reactivity. Interestingly,
we observed that Cys183 is located within a region devoid
of acidic residues. The presence of a basic residue (His154)
distant about 5Å from the side chain of Cys183 could lower
its pKa value, making it highly reactive (Figure 3(c)). His154
is located also in close proximity of Cys217; however, the
presence of several acidic residues located nearby the thiol
group may diminish its reactivity (Figure 3(d)). Further stud-
ies are necessary to clarify this matter.
1.2. Role of CA III as Antioxidant Agent. Important results
elucidating the physiological role of CA III in aging and
aging-related processes have been obtained from a study on
the nucleus pulposus (NP) phenotype [62]. NP is part of
the intervertebral disc, and its integrity is strictly related to
intervertebral disc degeneration. This, in turn, is associated
with low back and neck pain, leading to a very common
disability in the United States [63, 64]. One of the major
etiologic factors responsible for this pathological condition
is aging disc [65], which is characterized by the time-
dependent accumulation of cellular and molecular damage,
predominantly caused by oxidative and inﬂammatory pro-
cesses [65, 66]. Notably, NP is a hypoxic niche where the
two hypoxia-inducible CAs IX and XII are robustly expressed
and regulate intracellular pH level, which is essential for the
maintenance of cellular functions [67]. mRNA and protein
expression of CA III are hypoxia-sensitive, being upregulated
in low oxygen tension. However, unlike CAs IX and XII, CA
III expression is insensitive to HIF-1α, and this isoform does
not play a role in the regulation of intracellular pH homeo-
stasis [62], but it participates to the antioxidant defense
mechanism of NP cells. Indeed, NP cells silenced for CA
III expression showed high sensitivity to oxidative stress-
dependent apoptosis through caspase-3 activation. There-
fore, it has been suggested that mechanisms regulating CA
III expression may represent novel therapeutic targets to
reduce the negative eﬀects of oxidative damage associated
with aging in the degeneration of the intervertebral disc [62].
In agreement with this proposed protective role of CA III,
it was demonstrated that this protein inhibited apoptosis in
H2O2-stressed mature osteocytes [68] and in cotransfected
NIH/3T3 cells [69]. In particular, CA III expression increased
with osteoblast diﬀerentiation and was also involved in
diminishing ROS production and in protecting cells from
hypoxic stress [68]. Interesting data were also reported on
the repression of CA III gene transcription in Rat1 cells
expressing high level of Evi1 [70], a zinc ﬁnger protein
involved into cancer progression [71]. In these cells, Evi1
overexpression corresponded to a decreased level of CA III
and to an enhanced sensitivity to H2O2-induced apoptosis
[70]. These results may be used to exploit novel therapies tar-
geting oxidative stress.
Even though many papers describe the role of CA III in
cellular defense processes from oxidative insult, very little
information is available on the molecular mechanisms
responsible for this behavior. It has been suggested that the
antioxidant activity of this protein is related to the presence
of the above-described reactive cysteines, which in vivo are
S-glutathionylated [53]. To get more insights into this pro-
cess, Mallis and coworkers investigated in detail the chemical
modiﬁcation of CA III sulfhydryl groups upon exposure to
diﬀerent oxidant agents, such as H2O2, HOCl, or peroxy rad-
icals [72]. The authors revealed that the type of cysteine mod-
iﬁcation depends on cellular GSH content. Indeed, CA III
was reversibly S-glutathionylated when GSH concentration
was approximately equimolar to that of protein thiols,
whereas irreversible oxidation of cysteines to sulﬁnic or sul-
fonic acid derivatives occurred at low GSH levels. In agree-
ment with these data, CA III was found to be highly and
irreversibly oxidized in old rats with respect to young ani-
mals, since reduced GSH levels are a hallmark of aging.
Further insights into the role and mechanism of action of
CA III as antioxidant agent were obtained by Zimmerman
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et al. through the evaluation of S-glutathionylation and
irreversible oxidation of the two protein reactive cysteines
in the presence of increasing intensities of the oxidative stress
insult [73]. These analyses indicated that Cys183 and Cys188
were diﬀerentially oxidized in skeletal muscle when diﬀerent
oxidative stress conditions were induced. Speciﬁcally, only
Cys188 underwent reversible S-glutathionylation under a
mild or brief redox stress, involving about 20% of total skel-
etal muscle protein, whereas a prolonged or harsh stress pro-
duced irreversible oxidation of both sulfhydryl groups. Thus,
the high content of CA III in skeletal muscle could represent
a storage of reactive sulfhydryl moieties able to repair acute
and chronic oxidative insults. Moreover, in resting skeletal
muscle, less than 10% of CA III was S-glutathionylated, sug-
gesting that cysteine oxidation may represent a regulative
physiological mechanism performed by the enzyme within
the cell. A further proof of a possible involvement of CA III
in the glutathione-mediated antioxidant processes was
obtained by comparing the gene expression proﬁle of CA3-
knockout and wild type mice by microarray strategy [73].
Even though CA III-deﬁcient mice had a normal develop-
ment, fertility, and longevity, at least under experimental
standard laboratory conditions, they showed a transcriptional
alteration of more than 500 out of 12,000 genes analyzed;
most of them were associated with the GSH-mediated anti-
oxidative system [74].
1.3. Role of CA VII as Antioxidant Agent. Available data on
reactive cysteines in CA VII [51], together with the observa-
tion that this enzyme is expressed in tissues with a high
oxygen consumption rate (similarly to CA III), led us to
hypothesize that this protein may have a functional role
in vivo, that is of protecting cells from oxidative stress [52].
To test this hypothesis, human cancer (HeLa) cells, which
usually do not express endogenous CA VII, were transiently
transfected to express the wild-type protein, in the presence
or in the absence of oxidative stress. Consistent with our
hypothesis, cells expressing CA VII were less sensitive to apo-
ptosis induced by oxidative stress. This was clearly demon-
strated by measuring: (i) apoptotic protein levels and (ii)
apoptotic cells. In particular, mock-transfected cells showed
a signiﬁcant alteration in procaspases (8 and 3), Bcl-2 and
Bax levels after induction of oxidative stress, whereas corre-
sponding protein levels were almost unaltered in CA VII
C183
(a)
C188
K213
R189
D190
E214
(b)
C183
H154
(c)
H154
C217
E149
D152
E214
(d)
Figure 3: Chemical environment of CA III and VII reactive cysteines. (a) S-glutathionylated Cys183 of CA III showing two alternative
conformations. (b) S-glutathionylated Cys188 of CA III surrounded by Arg189, Asp190, Lys213, and Glu214 which aﬀect its pKa.
(c) Model of Cys183 in CA VII structure adjacent to His154. (d) Model of Cys217 in CA VII structure showing the nearby acidic
and basic residues.
5Oxidative Medicine and Cellular Longevity
expressing cells. Moreover, in the presence of oxidative stress,
an increase in CA VII expression was observed, suggesting an
attempt by the cell to protect itself by overexpressing the pro-
tein [52]. A further conﬁrmation of the importance of the
cysteine residues was obtained by performing the same
experiments in the presence of a mutated version of the pro-
tein, in which all cysteines were replaced by serines (TM-CA
VII). When cells were transiently transfected with the vector
encoding for the mutated protein and then stressed, no
protection was observed. Indeed, a similar alteration in
procaspase-3 and 8, Bax and Bcl-2 levels as well as apoptotic
cells, was observed for mock and TM-CA VII transfected
cells [52]. Thus, cysteine residues in CA VII exert a protective
functional role. Notably, the lack of the protective eﬀect was
not related to a diﬀerent catalytic activity of the mutated
enzyme, since it showed the same kinetic parameters of
native CA VII [52].
It is commonly accepted that increased levels of ROS are
related to oxidative stress, and may lead to the development
of many pathologies, including cancer [75–78]. Interestingly,
a reduced CA VII expression is observed in colorectal carci-
noma [79], thus allowing one to speculate that low protein
levels may be related to a higher cellular sensitivity to oxida-
tive stress and cancer progression.
2. Conclusions
In summary, cells have developed diﬀerent sophisticated
defense systems to counteract oxidative stress, and their abil-
ity to respond to ROS/RNS production is connected to aging,
cancer, and other disease states. Among the several molecular
systems, the contribution of CA III and CA VII as scavengers
towards oxidative insult has been recently proposed,
highlighting an unexpected functional role of these two
CAs. Notably, these CAs are abundantly expressed in tissues
such as brain, liver, and skeletal muscle, which present high
oxygen consumption rates. By means of diﬀerent approaches
including in vitro and in vivo experiments, it was shown that
CA III and CA VII exert their protective role due to the pres-
ence of reactive cysteines on their protein surface.
In particular, from a molecular point of view, the chem-
ical environment generated by residues nearby the reactive
sulfhydryls of CA III and CA VII assists the formation of
a thiolate anion which may undergo S-glutathionylation.
This reversible modiﬁcation is thought to protect cellular
proteins and preserves their functionality under oxidative
stress conditions.
Signiﬁcant ﬁndings on the peculiar role of these pro-
teins were obtained by the observation that both CA III
and CA VII protect cells from apoptosis induced by oxida-
tive agents, thus participating in the cellular defense system.
Further studies are necessary to better clarify their molecu-
lar and biological mechanism and a putative role as novel
antiaging molecules.
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